Cargando…
ODP322 Impact of Mifepristone on Liver Function and Resolution of Liver Steatosis in Patients with Cushing Syndrome – A Case Study
BACKGROUND: Hypercortisolism is a recognized cause of non-alcoholic fatty liver disease (NAFLD). Mifepristone (Korlym®, Corcept Therapeutics), a glucocorticoid receptor (GR) antagonist, is FDA-approved for the treatment of hyperglycemia in patients with endogenous Cushing syndrome (CS). Mifepristone...
Autores principales: | East, Honey E, Moraitis, Andreas G, Belanoff, Joseph K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627139/ http://dx.doi.org/10.1210/jendso/bvac150.1031 |
Ejemplares similares
-
SUN-460 Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
por: Moraitis, Andreas, et al.
Publicado: (2019) -
PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome
por: Moraitis, Andreas, et al.
Publicado: (2022) -
ODP309 Ectopic Cushing's Syndrome: Importance of Methodical Approach to Hide and Seek
por: de Souza, Tamara G, et al.
Publicado: (2022) -
ODP369 Weight Trajectory as a Predictor of Cushing's Disease
por: Thavaraputta, Subhanudh, et al.
Publicado: (2022) -
ODP304 Cyclic Cushing Disease: A Diagnostic Challenge
por: Zubiran, Rafael, et al.
Publicado: (2022)